CFM
SPRY icon

Catalyst Funds Management’s ARS Pharmaceuticals SPRY Stock Holding History

Catalyst Funds Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,000
Closed -$29K – 1142
2024
Q3 		$29K Buy
+2,000
New +$23.8K 0.01% 993

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Catalyst Funds Management's SPRY Position: Q4 2024 in Review

Catalyst Funds Management sold out of ARS Pharmaceuticals (SPRY) in Q4 2024, closing a stake of 2,000 shares — an estimated $29K sold.

Catalyst Funds Management first reported a position in SPRY in Q3 2024 and held it in 1 quarter. The position peaked at $29K in Q3 2024. 165 funds tracked by Wall St. Rank hold SPRY as of Q4 2024.

  • Catalyst Funds Management reported no remaining ARS Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 2,000 ARS Pharmaceuticals shares in Q4 2024, an estimated $29K.
  • Catalyst Funds Management first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Catalyst Funds Management's ARS Pharmaceuticals position peaked at $29K in Q3 2024.
  • 165 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.